WORLD NEWS

Prucalopride acts as a serotonin-4 (5-HT4) receptor agonist, stimulating colonic motility to help restore bowel regularity in patients suffering from chronic idiopathic constipation (CIC) in adults.

Mounjaro was first launched in India in late March 2025, initially available only in 2.5 mg and 5 mg vial forms.

Kymera’s molecular glue degraders (MGDs) are designed to selectively eliminate cyclin-dependent kinase 2 (CDK2), a protein that plays a crucial role in cell division and is often associated with the uncontrolled growth characteristic of many cancers.

The system automatically identifies key signs of hip osteoarthritis on X-rays, such as joint space narrowing, bone thickening (subchondral sclerosis), and bone spurs (osteophytes).

This innovative approach will allow scientists to study how the disease progresses in individual patients and develop personalized treatment plans tailored to each child’s unique heart condition.

This collaboration aims to support patients suffering from RAS-addicted cancers, a group of cancers driven by mutations in the RAS gene.

The new lens is intended for single-day use, offering a convenient and hygienic option for patients who have previously faced limited choices.

Under the terms of the agreement, Otsuka will obtain exclusive global rights to develop, manufacture, and commercialize HBM7020 outside of Greater China.

This recommendation is a crucial milestone, as no treatment for MASH is currently approved in the European Union.

The capital raised will primarily support the development of Actio’s two lead oral drug candidates: ABS-1230 and ABS-0871.